ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Contrast-enhanced ultrasound quantitative parameters for predicting benign and malignant greater omentum lesions: an applied study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo explore the value of contrast-enhanced ultrasound (CEUS) quantitative parameters in differentiating benign and malignant diseases of the greater omentum and to establish a new CEUS Greater Omentum Imaging Reporting and Data System (CEUS-GOIRADS).
methodsWe analyzed 15 CEUS parameters from 124 patients undergoing omental biopsy (2020–2024) to develop a noninvasive predictive model and assess its diagnostic value. Statistically significant parameters were further analyzed using receiver operating characteristic (ROC) curve cutoff values to determine odds ratios (ORs) for each group. A CEUS-OS was developed for each patient, and ROC curve analysis was performed to evaluate its efficacy in distinguishing between benign and malignant omental diseases.
resultsAmong 124 patients meeting the inclusion criteria, 76 had malignant lesions and 48 had benign lesions. Multivariate analysis identified three out of 15 CEUS parameters—IMAX, Fs50, and WioAUC—as associated with malignant lesions of the greater omentum. The noninvasive predictive model demonstrated a sensitivity of 90.7% and specificity of 90.5% for diagnosing malignant omental lesions. Furthermore, the established CEUS-GOIRADS grading system showed a sensitivity of 94.7% and specificity of 89.6% for differentiating between benign and malignant omental diseases.
conclusionQuantitative analysis of CEUS parameters provides effective indicators for determining the nature of greater omental lesions. This non-invasive imaging modality can reliably predict whether omental lesions are benign or malignant. The CEUS-GOIRADS demonstrates high sensitivity and specificity in differentiating benign from malignant omental diseases, suggesting its potential as a CEUS-GOIRADS valuable tool in the multi-step diagnostic evaluation of patients with various omental pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.